Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accounts Payables: 2010-2025

Historic Accounts Payables for Aytu Biopharma (AYTU) over the last 16 years, with Jun 2025 value amounting to $10.6 million.

  • Aytu Biopharma's Accounts Payables fell 8.67% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year decrease of 8.67%. This contributed to the annual value of $10.6 million for FY2025, which is 2.78% up from last year.
  • Per Aytu Biopharma's latest filing, its Accounts Payables stood at $10.6 million for FY2025, which was up 2.78% from $10.3 million recorded in FY2024.
  • Aytu Biopharma's Accounts Payables' 5-year high stood at $19.3 million during FY2021, with a 5-year trough of $10.3 million in FY2024.
  • For the 3-year period, Aytu Biopharma's Accounts Payables averaged around $11.5 million, with its median value being $10.6 million (2025).
  • Per our database at Business Quant, Aytu Biopharma's Accounts Payables soared by 65.42% in 2021 and then tumbled by 42.94% in 2022.
  • MRY analysis of 5 years shows Aytu Biopharma's Accounts Payables stood at $19.3 million in 2021, then plummeted by 42.94% to $11.0 million in 2022, then increased by 22.67% to $13.5 million in 2023, then dropped by 23.48% to $10.3 million in 2024, then increased by 2.78% to $10.6 million in 2025.
  • Its last three reported values are $10.6 million in FY2025, $10.3 million for FY2024, and $13.5 million during FY2023.